Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note released on Friday,Benzinga reports. They currently have a $12.00 price target on the stock.

TSHA has been the subject of a number of other research reports. Bank of America initiated coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Wednesday, October 8th. Needham & Company LLC boosted their price objective on shares of Taysha Gene Therapies from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Wells Fargo & Company lifted their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Finally, Robert W. Baird lifted their price target on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Taysha Gene Therapies Stock Down 7.1%

Shares of NASDAQ TSHA opened at $4.72 on Friday. The stock has a market cap of $1.29 billion, a P/E ratio of -13.88 and a beta of 0.99. The firm has a 50 day moving average price of $3.47 and a 200 day moving average price of $2.70. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.48 and a current ratio of 12.48. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The firm had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. Analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently added to or reduced their stakes in the company. ST Germain D J Co. Inc. increased its holdings in Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. Granahan Investment Management LLC increased its holdings in Taysha Gene Therapies by 0.3% during the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock worth $2,281,000 after buying an additional 4,412 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after buying an additional 6,350 shares during the last quarter. Prudential Financial Inc. increased its holdings in Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after buying an additional 7,650 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.